We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
卡瑞利珠单抗联合 TACE 对伴微血管侵犯肝细胞癌患者肿瘤标志物、 血管生成因子和血清 PD-1、PD-L1 的影响.
- Authors
汪景洲; 王宇鹏; 刘航成; 梁 峰; 赵清涛
- Abstract
Objective: To observe the effects of carrelizumab combined with transcatheter arterial chemoembolization (TACE) on tumor markers, angiogenic factors, serum programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) in patients with hepatocellular carcinoma (HCC) with microvascular invasion. Methods: 121 HCC patients with microvascular invasion who were admitted to our hospital from June 2021 to July 2023 were divided into control group (n=60, receiving radical resection of liver cancer and TACE treatment) and study group (n=61, receiving carrelizumab treatment on the basis of control group) according to the random number table method. The efficacy, serum tumor marker levels [alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), abnormal prothrombin (PIVKA-II), carbohydrate antigen 199 (CA199)], angiogenesis factor levels [vascular endothelial growth factor receptor 2 (VEGF-R2), angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF)], serum PD-1 and PD-L1 levels, adverse reactions were compared between two groups (P>0.05). Results: Compared with control group, the total clinical effective rate in study group was higher (P<0.05). Compared with control group after treatment, CEA, AFP, CA199, PIVKA-II, VEGF, VEGF-R2, Ang-2, PD-1 and PD-L1 in study group were lower(P<0.05). There was no difference in the incidence of adverse reactions between two groups(P>0.05). Conclusion: Carrelizumab combined with TACE in the treatment of HCC patients with microvascular invasion, which can improve the serum tumor markers, inhibit angiogenesis and reduce serum PD-1 and PD-L1 levels, and effectively control disease progression.
- Publication
Progress in Modern Biomedicine, 2024, Vol 24, Issue 9, p1678
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2024.09.015